| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Robert E McCu. Clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia. Evidence-based mental health. vol 10. issue 2. 2007-05-22. PMID:17459988. |
clozapine improves symptoms but not quality of life compared with other second-generation antipsychotics in people with treatment resistant schizophrenia. |
2007-05-22 |
2023-08-12 |
Not clear |
| Andrew J Goudie, Gillian D Cooper, Jon C Cole, Harry R Sumnal. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. Journal of psychopharmacology (Oxford, England). vol 21. issue 2. 2007-05-15. PMID:17329298. |
our findings, in conjunction with other actions of cyproheptadine -- induction of weight gain, alleviation of clozapine withdrawal, anxiolytic actions, alleviation of 'typical' apd-induced motoric side effects, and some preliminary clinical findings -- suggest that further study of cyproheptadine in conjunction with a 'typical' apd for the possible treatment of schizophrenia is merited at both pre-clinical and clinical levels. |
2007-05-15 |
2023-08-12 |
rat |
| Maria Bjarnadottir, Dinah L Misner, Sascha Haverfield-Gross, Silas Bruun, Vignir G Helgason, Hreinn Stefansson, Arnar Sigmundsson, David R Firth, Berit Nielsen, Ragnheidur Stefansdottir, Thomas J Novak, Kari Stefansson, Mark E Gurney, Thorkell Andresso. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 27. issue 17. 2007-05-15. PMID:17460065. |
furthermore, we showed that nrg1+/- mutant mice display behavioral abnormalities that are reversed by clozapine, an atypical antipsychotic drug used for the treatment of schizophrenia. |
2007-05-15 |
2023-08-12 |
mouse |
| Lu-xian Lü, Su-qin Guo, Wei Chen, Qiang Li, Jun Cheng, Jing-hua Gu. [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA. vol 24. issue 11. 2007-05-09. PMID:15567770. |
[effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]. |
2007-05-09 |
2023-08-12 |
Not clear |
| Yu-Tao Xiang, Yong-Zhen Weng, Chi-Ming Leung, Wai-Kwong Tang, Gabor Sandor Ungvar. Clinical correlates of clozapine prescription for schizophrenia in China. Human psychopharmacology. vol 22. issue 1. 2007-05-02. PMID:17191268. |
clinical correlates of clozapine prescription for schizophrenia in china. |
2007-05-02 |
2023-08-12 |
Not clear |
| Yu-Tao Xiang, Yong-Zhen Weng, Chi-Ming Leung, Wai-Kwong Tang, Gabor Sandor Ungvar. Clinical correlates of clozapine prescription for schizophrenia in China. Human psychopharmacology. vol 22. issue 1. 2007-05-02. PMID:17191268. |
few studies have investigated the prescription patterns of clozapine in outpatients with schizophrenia in china. |
2007-05-02 |
2023-08-12 |
Not clear |
| Pietro Gareri, Pasquale De Fazio, Salvatore De Fazio, Norma Marigliano, Guido Ferreri Ibbadu, Giovambattista De Sarr. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs & aging. vol 23. issue 12. 2007-05-01. PMID:17154659. |
use of clozapine, for example, is limited by the risk of agranulocytosis, whereas this is not a disadvantage of olanzapine, risperidone, quetiapine and, more recently, ziprasidone, which are being widely used with good results in schizophrenia. |
2007-05-01 |
2023-08-12 |
Not clear |
| Eromona Whiskey, David Taylo. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS drugs. vol 21. issue 1. 2007-05-01. PMID:17190527. |
clozapine remains the antipsychotic of choice for refractory schizophrenia despite its propensity for serious blood disorders. |
2007-05-01 |
2023-08-12 |
Not clear |
| W W Blessing, Y Ootsuk. Activation of dopamine D2 receptors in the CNS inhibits sympathetic cutaneous vasomotor alerting responses (SCVARs), contributing to clozapine's SCVAR-inhibiting action. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 2. 2007-04-24. PMID:17055139. |
mechanisms underlying clozapine's scvar-inhibiting effect include dopamine d(2) receptor agonism, not dopamine d(2) receptor antagonism, calling into question the mechanism of the drug's therapeutic action in schizophrenia. |
2007-04-24 |
2023-08-12 |
rat |
| Charalampos I Mitsonis, Nikolaos P Dimopoulos, Panagiotis A Mitropoulos, Evangelia G Kararizou, Alexandra N Katsa, Fivos E Tsakiris, Maria Nefeli E Katsano. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 2. 2007-04-24. PMID:17092620. |
the aim of this study was to investigate whether augmentation of clozapine with aripiprazole improves clinically significant residual symptoms in stabilized outpatients with chronic schizophrenia. |
2007-04-24 |
2023-08-12 |
Not clear |
| Houman Homayoun, Bita Moghadda. Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biological psychiatry. vol 61. issue 5. 2007-04-17. PMID:17046721. |
mechanisms underlying clozapine's better clinical efficacy in schizophrenia remain poorly understood. |
2007-04-17 |
2023-08-12 |
Not clear |
| Zhu Li, Mei Huang, Adam J Prus, Jin Dai, Herbert Y Meltze. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain research. vol 1134. issue 1. 2007-04-05. PMID:17207474. |
clozapine, risperidone, olanzapine and ziprasidone, to improve cognitive function in schizophrenia. |
2007-04-05 |
2023-08-12 |
rat |
| Yujuan La, Chunling Wan, Hui Zhu, Yifeng Yang, Yongshuo Chen, Yuxi Pan, Baohu Ji, Guoyin Feng, Lin H. Hippocampus protein profiling reveals aberration of malate dehydrogenase in chlorpromazine/clozapine treated rats. Neuroscience letters. vol 408. issue 1. 2007-04-03. PMID:16989946. |
chlorpromazine and clozapine are antipsychotic agents used to relieve symptoms of early-diagnosed schizophrenia. |
2007-04-03 |
2023-08-12 |
rat |
| Wen-Jun Ga. Acute clozapine suppresses synchronized pyramidal synaptic network activity by increasing inhibition in the ferret prefrontal cortex. Journal of neurophysiology. vol 97. issue 2. 2007-04-02. PMID:17182915. |
these results suggest that the therapeutic actions of clozapine in alleviating the positive symptoms of schizophrenia are achieved, at least partially, through the readjustment of synaptic balance between the excitation and inhibition in the prefrontal cortical circuitry. |
2007-04-02 |
2023-08-12 |
Not clear |
| Mark A Geye. The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps? Neurotoxicity research. vol 10. issue 3-4. 2007-03-20. PMID:17197371. |
both ppi and cognitive deficits in schizophrenia patients are not reversed by first generation antipsychotics but may be attenuated by clozapine. |
2007-03-20 |
2023-08-12 |
human |
| Jose de Leon, Francisco J Diaz, Richard C Josiassen, Thomas B Cooper, George M Simpso. Weight gain during a double-blind multidosage clozapine study. Journal of clinical psychopharmacology. vol 27. issue 1. 2007-03-20. PMID:17224708. |
fifty treatment-refractory schizophrenia patients were randomized to 100-, 300-, or 600-mg/d doses of clozapine for a 16-week, double-blind treatment in a research ward. |
2007-03-20 |
2023-08-12 |
Not clear |
| Julie Marchand, Sylvain Grigno. A case-control study of patients with resistant schizophrenia after clozapine discontinuation. Journal of clinical psychopharmacology. vol 27. issue 1. 2007-03-20. PMID:17224722. |
a case-control study of patients with resistant schizophrenia after clozapine discontinuation. |
2007-03-20 |
2023-08-12 |
Not clear |
| Maria A Rettenbacher, Christoph Ebenbichler, Alex Hofer, Georg Kemmler, Susanne Baumgartner, Monika Edlinger, Martina Hummer, Monika Lechleitner, W Wolfgang Fleischhacke. Early changes of plasma lipids during treatment with atypical antipsychotics. International clinical psychopharmacology. vol 21. issue 6. 2007-03-16. PMID:17012984. |
we conducted a prospective, open study in schizophrenia patients in order to compare body weight and serum lipids during treatment with amisulpride, ziprasidone, clozapine or olanzapine over a period of 4 weeks. |
2007-03-16 |
2023-08-12 |
Not clear |
| Seiya Miyamot. [Critical review of mechanisms of action of second-generation antipsychotic drugs]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 26. issue 5-6. 2007-03-06. PMID:17240845. |
the advent of second-generation antipsychotics (sga) in the wake of clozapine, the prototype for atypical antipsychotics, represents a breakthrough in the pharmacologic treatment of schizophrenia. |
2007-03-06 |
2023-08-12 |
Not clear |
| Jingping Zhao, Xiaolin He, Zhening Liu, Desen Yan. The effects of clozapine on cognitive function and regional cerebral blood flow in the negative symptom profile schizophrenia. International journal of psychiatry in medicine. vol 36. issue 2. 2007-02-26. PMID:17154147. |
the effects of clozapine on cognitive function and regional cerebral blood flow in the negative symptom profile schizophrenia. |
2007-02-26 |
2023-08-12 |
Not clear |